Business Wire

CA-NEAT

22.7.2020 15:02:05 CEST | Business Wire | Press release

Share
Neat Launches Subscription Service for Zoom Customers Outside the US and Announces Additional Investment from Zoom

Neat , a Norwegian company whose pioneering team have been at the cutting edge of video communications for decades, today announced its Neat as a Service (NaaS) subscription offering. NaaS makes it quick and easy for Zoom customers outside the US to deploy Neat hardware devices in their meeting spaces. Neat and Zoom have also disclosed that Zoom Video Communications, Inc. (NASDAQ: ZM) has made an additional financial investment in Neat.

"Zoom and Neat together are making it easy for customers to expand their video conferencing capabilities. Our additional investment in Neat reflects our conviction that Neat's devices are an outstanding complement to Zoom's communications platform," said Eric S. Yuan, Zoom CEO. "We believe Neat offers innovative technology that ensures Zoom customers enjoy an incredible meeting room experience."

Aligned with Zoom's recently introduced Hardware as a Service (HaaS), NaaS is provided directly by Neat and expands the reach of Zoom HaaS beyond the US, enabling Zoom customers globally to consume Neat devices. Among other things, it's an ideal solution for customers with offices and teams scattered throughout different countries, as they can ensure a consistent global experience for all users.

As the new normal forces people around the world to adapt their ways of working, both in offices and remotely, video conferencing is proving to be a key tool in supporting continued productivity and driving stronger collaboration. NaaS makes it seamless for customers with a Zoom Rooms license to equip their meeting spaces with any of Neat's world-class devices: Neat Bar and Neat Pad, and Neat Board when it begins shipping at the end of October. With easy ordering and set up, customers can quickly enjoy all the benefits of deploying Zoom Rooms the Neat way, including receiving all the latest software releases and support from Zoom.

"Zoom customers globally are transitioning back to a mix of office and remote work, and need a scalable, cost-effective way to quickly expand their Zoom deployments in their meeting spaces," said Jeff Smith, Head of Zoom Rooms, Zoom. "Neat's innovative devices deliver a great user experience and are easy to install and manage. NaaS builds on that by giving customers the purchasing flexibility and choice they need."

"Subscription models such as Neat as a Service are the future of video conferencing since they eliminate expensive up-front costs and the complexity of deployment and ongoing support," said Roopam Jain, Industry Director, Unified Communications and Collaboration at Frost and Sullivan. "Video meetings are a better way to connect and collaborate. Particularly today, users need video that just works, whether they are in their home offices or meeting rooms."

Customers currently pay for their Zoom Rooms licenses through a subscription service from Zoom. With NaaS, they can use a subscription model for Neat devices as well, making the budgeting and managing of their Zoom Rooms even simpler.

NaaS is available now at neat.no and offers a 24-month plan with flexible payment options so customers can select the plan that best suits their requirements and budget. Neat Bar subscriptions start from as low as US$ 100/mo with an annual billing option. After the initial 24-month term, customers can then choose to upgrade their Neat system for the latest model with the newest hardware technology. Customers can also easily add further Neat devices to their existing plan to keep everything on a single contract.

"Neat was designed for Zoom, with the sole purpose of delivering a delightful meeting room experience to Zoom customers. We have achieved that by providing Zoom customers around the globe with our beautifully designed, simple to set up, feature-rich devices," said Simen Teigre, Neat CEO. "NaaS is the next step in our mission, offering a flexible subscription service that allows businesses to expand their Zoom solution with Zoom Rooms in a hassle-free way."

About Neat

Neat designs simple and elegant video meeting devices that just work. The company was founded in Oslo, Norway, by a team that for decades have shaped game-changing innovations for some of the most recognized brands in video communications. All Neat products are available to buy directly online from neat.no and ship globally. Offering unique features, they are easy to set up and use, making Zoom Rooms the smoothest and best it's ever been. For more information on Zoom Rooms the Neat way, visit neat.no or @neat_no .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye